Balversa
(erdafitinib) Janssen

Composition:

• Available in film-coated tablet with each contains 3 mg, 4 mg or 5 mg erdafitinib for oral administration

Indication:

• For the treatment of adult patients with locally advanced or metastatic urothelial carcinoma, that has:
• susceptible FGFR3 or FGFR2 genetic alterations, and      
• progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy

Drug information including formulation, indication, administration and/or presentation updated, registered or launched in Hong Kong within one year prior to the date written is regarded as new in The Pace.
The information in The Pace is provided as a courtesy service to our readers and is intended for medical professional reference only. Please peruse the latest local prescription information prior to prescription.